Related Experiment Video
Updated: Jun 25, 2026
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis
U C Bang1, C Nøjgaard, P K Andersen
1Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark. ulrichbangbang@gmail.com
Alimentary Pharmacology & Therapeutics
|February 25, 2009
Summary
Nitroglycerin may help prevent acute pancreatitis after ERCP, a serious complication. While overall results are supportive, the dermal route, though preferred, did not show statistically significant preventive effects in this meta-analysis.
Area of Science:
- Gastroenterology
- Clinical Pharmacology
Background:
- Acute pancreatitis is a severe complication following Endoscopic Retrograde Cholangiopancreatography (ERCP).
- Preventive strategies for post-ERCP pancreatitis are crucial for patient safety.
Purpose of the Study:
- To evaluate the efficacy of nitroglycerin in preventing post-ERCP pancreatitis.
- This meta-analysis synthesized data from randomized clinical trials.
Main Methods:
- Searched major databases (PubMed, Embase, Cochrane Library) and conference abstracts (2004-2008).
- Utilized MeSH terms 'pancreatitis' combined with various nitroglycerin-related terms.
- Included five randomized clinical studies in the meta-analysis.
Main Results:
- Meta-analysis of five studies showed a reduced risk of post-ERCP pancreatitis with nitroglycerin (RR 0.61).
- Number needed to treat (NNT) was 26, indicating potential benefit.
- Dermal nitroglycerin showed a trend towards prevention (RR 0.66) but lacked statistical significance.
- Increased risks of hypotension (RR 2.25) and headache (RR 3.64) were observed; no mortality difference.
Conclusions:
- The meta-analysis supports the use of nitroglycerin for preventing post-ERCP pancreatitis.
- The preferred dermal route did not achieve statistical significance in prevention.
- Further research may be needed to optimize nitroglycerin's role in post-ERCP pancreatitis prophylaxis.
Related Concept Videos
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
01:26Endoscopic Procedures V: ERCP
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...
Patient...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...